Lead Candidate Finalization and a Comprehensive Biological Assessment of a New Class of Pneumococcal Vaccines
Award last edited on: 2/14/2019

Sponsored Program
Awarding Agency
Total Award Amount
Award Phase
Solicitation Topic Code

Principal Investigator
Charles Houston Jones

Company Information

Abcombi Biosciences Inc

303 Furnas Hall
Buffalo, NY 14260
   (919) 619-6772
Location: Single
Congr. District: 26
County: Erie

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
Phase I Amount
The illnesses caused by Streptococcus pneumoniae's transition from carriage to disease results in a mortality rate between approximately 3-10% in adults and 12-25% in elderly patients in the United States. Furthermore, pneumococcal disease devastates resource-poor countries, causing an estimated 476,000 (~32% of vaccine-preventable deaths in children below age five) to succumb to pneumococcal infection annually. The most effective vaccines, polysaccharide protein conjugates, require a complicated process of collecting polysaccharide antigens from pneumococci serotypes and conjugating them to a protein adjuvant. Abcombi Biosciences has developed a pneumococcal vaccine using liposomal encapsulation of polysaccharides (LEPS), which has demonstrated conjugate-like efficacy against 70+ serotypes of S. pneumoniae via animal challenge models and opsonophagocytosis activity (OPA). To our knowledge, this represents the broadest protection demonstrated by a conjugate-like vaccine to date using an OPA assay, which is recognized as the gold standard for clinical efficacy against S. pneumoniae. In the proposed Phase I application, Abcombi Biosciences outlines a plan to overcome the risk for potential negative side effects associated with the LEPS vaccine's current formulation. Briefly, the inclusion one pneumococcal virulent protein (GlpO) and his-tags creates the potential for off-target effects. In this approach, serum from GlpO- vaccinated mice will be evaluated for cross-reactivity against a representative set commensal microflora using immunofluorescence and OPA assays. In addition, a portfolio of protein-to-liposome attachment strategies will be immunologically characterized by quantifying antibody titers, antibody class shifting, and OPA activity. Upon completing these studies, we will consult with our CMC and regulatory advisors to select the most promising candidate for long-term manufacturing. This candidate will then be subjected to a comprehensive immunological and toxicological assessment in preparation for IND-enabling studies. This work will serve as the basis for process optimization studies that will be conducted in a future Phase II study.

Project Terms:
Address; Adjuvant; Adult; Adverse effects; Adverse reactions; Age; Animals; Antibodies; Antibody titer measurement; Antigens; Automobile Driving; Bacteremia; Bacteria; Bacterial Meningitis; base; Benchmarking; Binding; Biological; Biological Assay; Biological Sciences; Biotin; Blood Circulation; Carrier Proteins; Chemicals; Chemistry; Child; Clinical; clinical efficacy; commensal microbes; Communities; Consult; Country; Coupling; cross reacting material 197; cross reactivity; design; Development; Disease; Effectiveness; experience; Formulation; Future; Glycoconjugates; Gold; Herd Immunity; high risk; Human; Immunize; Immunofluorescence Immunologic; immunogenic; immunogenicity; Immunoglobulin G; Immunoglobulin M; Immunologics; Individual; Infant; innovation; interest; Lead; lead candidate; Liposomes; manufacturing process; Measures; Mediating; Modeling; mortality; Mus; older patient; Otitis Media; Outcome; pathogen; patient population; Performance; Pharmacologic Substance; Phase; phase 2 study; Pneumococcal Infections; Pneumococcal vaccine; Pneumonia; Polysaccharides; Preparation; prevent; preventable death; Process; process optimization; Proteins; Protocols documentation; Reaction; Research; Resources; Risk; Serotyping; Serum; Small Business Innovation Research Grant; Streptavidin; Streptococcus pneumoniae; success; Sulfhydryl Compounds; Surface; Toxicology; Translations; United States; Vaccinated; Vaccination; vaccine candidate; Vaccine Design; vaccine development; Vaccines; Virulence; Virulent; Work;

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
Phase II Amount